Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients

Genome Medicine

Volumn 9, Issue 1, 2017, Pages

  Galloway Peña, Jessica R ^a   Smith, Daniel P ^b   Sahasrabhojane, Pranoti ^a   Wadsworth, W Duncan ^c   Fellman, Bryan M ^a   Ajami, Nadim J ^b   Shpall, Elizabeth J ^a   Daver, Naval ^a   Guindani, Michele ^d   Petrosino, Joseph F ^b   Kontoyiannis, Dimitrios P ^a   Shelburne, Samuel A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Rice University   (United States)

^d Ringgold Standard Institution Informatics   (United States)

Author keywords

Antibiotics; Chemotherapy; Leukemia; Microbiome; Temporal variability

Indexed keywords

ANTILEUKEMIC AGENT; RNA 16S; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT;

ACUTE MYELOID LEUKEMIA; ADULT; ADVERSE OUTCOME; AGED; ANALYTICAL PARAMETERS; ARTICLE; CANCER PATIENT; COHORT ANALYSIS; COMMUNITY STRUCTURE; CONTROLLED STUDY; FECES ANALYSIS; FEMALE; HOSPITAL PATIENT; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION RISK; INTESTINE FLORA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MICROBIAL DIVERSITY; MICROBIOME; MOUTH FLORA; NONHUMAN; POPULATION ABUNDANCE; RNA SEQUENCE; SHANNON DIVERSITY INDEX; BACTERIUM; DNA SEQUENCE; DRUG EFFECTS; FECES; GENETICS; ISOLATION AND PURIFICATION; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; SALIVA;

AGED; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BACTERIA; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RNA, RIBOSOMAL, 16S; SALIVA; SEQUENCE ANALYSIS, DNA;

EID: 85014085180     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/s13073-017-0409-1     Document Type: Article

References (47)

1. Cameron SJ, Huws SA, Hegarty MJ, Smith DP, Mur LA. The human salivary microbiome exhibits temporal stability in bacterial diversity. FEMS Microbiol Ecol. 2015;91(9):fiv091.
2. Claesson MJ, Cusack S, O'Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4586-91.
3. Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. Bacterial community variation in human body habitats across space and time. Science. 2009;326(5960):1694-7.
4. Oh J, Byrd AL, Park M, Program NCS, Kong HH, Segre JA. Temporal stability of the human skin microbiome. Cell. 2016;165(4):854-66.
5. Moya A, Ferrer M. Functional redundancy-induced stability of gut microbiota subjected to disturbance. Trends Microbiol. 2016;24(5):402-13.
6. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489(7415):220-30.
7. Halpin AL, de Man TJ, Kraft CS, Perry KA, Chan AW, Lieu S, et al. Intestinal microbiome disruption in patients in a long-term acute care hospital: a case for development of microbiome disruption indices to improve infection prevention. Am J Infect Control. 2016;44(7):830-6.
8. Laufer Halpin A, McDonald LC. The dawning of microbiome remediation for addressing antibiotic resistance. Clin Infect Dis. 2016;62(12):1487-8.
9. Lei YM, Nair L, Alegre ML. The interplay between the intestinal microbiota and the immune system. Clin Res Hepatol Gastroenterol. 2015;39(1):9-19.
10. Parfrey LW, Knight R. Spatial and temporal variability of the human microbiota. Clin Microbiol Infect. 2012;18 Suppl 4:8-11.
11. Zaborin A, Smith D, Garfield K, Quensen J, Shakhsheer B, Kade M, et al. Membership and behavior of ultra-low-diversity pathogen communities present in the gut of humans during prolonged critical illness. MBio. 2014;5(5):e01361-01314.
12. Belstrom D, Holmstrup P, Bardow A, Kokaras A, Fiehn NE, Paster BJ. Temporal stability of the salivary microbiota in oral health. PLoS One. 2016;11(1):e0147472.
13. Caporaso JG, Lauber CL, Costello EK, Berg-Lyons D, Gonzalez A, Stombaugh J, et al. Moving pictures of the human microbiome. Genome Biol. 2011;12(5):R50.
14. de Meij TG, Budding AE, de Groot EF, Jansen FM, Frank Kneepkens CM, Benninga MA, et al. Composition and stability of intestinal microbiota of healthy children within a Dutch population. FASEB J. 2016;30(4):1512-22.
15. Flores GE, Caporaso JG, Henley JB, Rideout JR, Domogala D, Chase J, et al. Temporal variability is a personalized feature of the human microbiome. Genome Biol. 2014;15(12):531.
16. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207-14.
17. Falony G, Joossens M, Vieira-Silva S, Wang J, Darzi Y, Faust K, et al. Population-level analysis of gut microbiome variation. Science. 2016;352(6285):560-4.
18. Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850-9.
19. Angelberger S, Reinisch W, Makristathis A, Lichtenberger C, Dejaco C, Papay P, et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol. 2013;108(10):1620-30.
20. Martinez C, Antolin M, Santos J, Torrejon A, Casellas F, Borruel N, et al. Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission. Am J Gastroenterol. 2008;103(3):643-8.
21. Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012;55(7):905-14.
22. Jenq RR, Ubeda C, Taur Y, Menezes CC, Khanin R, Dudakov JA, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med. 2012;209(5):903-11.
23. Montassier E, Al-Ghalith GA, Ward T, Corvec S, Gastinne T, Potel G, et al. Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection. Genome Med. 2016;8(1):49.
24. Taur Y, Jenq RR, Perales MA, Littmann ER, Morjaria S, Ling L, et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood. 2014;124(7):1174-82.
25. Galloway-Pena JR, Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, Daver NG, et al. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer. 2016;122(14):2186-96.
26. Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis. 2008;197(3):435-8.
27. Human Microbiome Project Consortium. A framework for human microbiome research. Nature. 2012;486(7402):215-21.
28. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 2013;41(Database issue):D590-6.
29. McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One. 2013;8(4):e61217.
30. Morgan XC, Huttenhower C. Human microbiome analysis. PLoS Comput Biol. 2012;8(12):e1002808.
31. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, et al. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients
32. Montalban-Bravo G, Garcia-Manero G. Novel drugs for older patients with acute myeloid leukemia. Leukemia. 2015;29(4):760-9.
33. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-9.
34. The Integrative Human Microbiome Project. Dynamic analysis of microbiome-host omics profiles during periods of human health and disease. Cell Host Microbe. 2014;16(3):276-89.
35. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4554-61.
36. Modi SR, Collins JJ, Relman DA. Antibiotics and the gut microbiota. J Clin Invest. 2014;124(10):4212-8.
37. Montassier E, Gastinne T, Vangay P, Al-Ghalith GA, Bruley des Varannes S, Massart S, et al. Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther. 2015;42(5):515-28.
38. Derrien M, Belzer C, de Vos WM. Akkermansia muciniphila and its role in regulating host functions. Microb Pathog. 2016. doi: 10.1016/j.micpath.2016.02.005. http://www.sciencedirect.com/science/article/pii/S0882401015301789. [Epub ahead of print].
39. Kozakova H, Schwarzer M, Tuckova L, Srutkova D, Czarnowska E, Rosiak I, et al. Colonization of germ-free mice with a mixture of three Lactobacillus strains enhances the integrity of gut mucosa and ameliorates allergic sensitization. Cell Mol Immunol. 2016;13(2):251-62.
40. Raymond F, Ouameur AA, Deraspe M, Iqbal N, Gingras H, Dridi B, et al. The initial state of the human gut microbiome determines its reshaping by antibiotics. ISME J. 2016;10(3):707-20.
41. Reunanen J, Kainulainen V, Huuskonen L, Ottman N, Belzer C, Huhtinen H, et al. Akkermansia muciniphila adheres to enterocytes and strengthens the integrity of the epithelial cell layer. Appl Environ Microbiol. 2015;81(11):3655-62.
42. Mathewson ND, Jenq R, Mathew AV, Koenigsknecht M, Hanash A, Toubai T, et al. Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol. 2016;17(5):505-13.
43. Shono Y, Docampo MD, Peled JU, Perobelli SM, Velardi E, Tsai JJ, et al. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med. 2016;8(339):339ra371.
44. Lam EK, Tai EK, Koo MW, Wong HP, Wu WK, Yu L, et al. Enhancement of gastric mucosal integrity by Lactobacillus rhamnosus GG. Life Sci. 2007;80(23):2128-36.
45. Yu Q, Yuan L, Deng J, Yang Q. Lactobacillus protects the integrity of intestinal epithelial barrier damaged by pathogenic bacteria. Front Cell Infect Microbiol. 2015;5:26.
46. Bernbom N, Licht TR, Brogren CH, Jelle B, Johansen AH, Badiola I, et al. Effects of Lactococcus lactis on composition of intestinal microbiota: role of nisin. Appl Environ Microbiol. 2006;72(1):239-44.
47. Araos R, Tai AK, Snyder GM, Blaser MJ, D'Agata EM. Predominance of Lactobacillus spp. among patients who do not acquire multidrug-resistant organisms. Clin Infect Dis. 2016;63(7):937-43.